JP2014532654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532654A5 JP2014532654A5 JP2014539025A JP2014539025A JP2014532654A5 JP 2014532654 A5 JP2014532654 A5 JP 2014532654A5 JP 2014539025 A JP2014539025 A JP 2014539025A JP 2014539025 A JP2014539025 A JP 2014539025A JP 2014532654 A5 JP2014532654 A5 JP 2014532654A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nerve
- amount
- cardiac
- sufficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 210000005036 nerve Anatomy 0.000 claims 21
- 239000002368 cardiac glycoside Substances 0.000 claims 18
- 229940097217 cardiac glycoside Drugs 0.000 claims 18
- 229930002534 steroid glycoside Natural products 0.000 claims 18
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 10
- 150000008143 steroidal glycosides Chemical class 0.000 claims 8
- 210000002569 neuron Anatomy 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229960002036 phenytoin Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 1
- 206010029315 Neuromuscular blockade Diseases 0.000 claims 1
- 210000003050 axon Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 claims 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical group C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 210000004116 schwann cell Anatomy 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161551921P | 2011-10-26 | 2011-10-26 | |
| US61/551,921 | 2011-10-26 | ||
| PCT/US2012/062006 WO2013063331A1 (en) | 2011-10-26 | 2012-10-25 | Agents, methods, and devices for affecting nerve function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014532654A JP2014532654A (ja) | 2014-12-08 |
| JP2014532654A5 true JP2014532654A5 (enExample) | 2015-12-17 |
Family
ID=48168518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539025A Pending JP2014532654A (ja) | 2011-10-26 | 2012-10-25 | 神経機能に影響を及ぼす薬剤、方法、およびデバイス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150202220A1 (enExample) |
| EP (1) | EP2770992A4 (enExample) |
| JP (1) | JP2014532654A (enExample) |
| CN (2) | CN105688214A (enExample) |
| CA (1) | CA2853466A1 (enExample) |
| WO (1) | WO2013063331A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
| US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
| US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
| US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
| US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
| CN101076290B (zh) | 2004-12-09 | 2011-11-23 | 铸造品股份有限公司 | 主动脉瓣修复 |
| WO2012161875A1 (en) | 2011-04-08 | 2012-11-29 | Tyco Healthcare Group Lp | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
| US8663190B2 (en) | 2011-04-22 | 2014-03-04 | Ablative Solutions, Inc. | Expandable catheter system for peri-ostial injection and muscle and nerve fiber ablation |
| US9237925B2 (en) | 2011-04-22 | 2016-01-19 | Ablative Solutions, Inc. | Expandable catheter system for peri-ostial injection and muscle and nerve fiber ablation |
| US20130053792A1 (en) | 2011-08-24 | 2013-02-28 | Ablative Solutions, Inc. | Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation |
| US9056185B2 (en) | 2011-08-24 | 2015-06-16 | Ablative Solutions, Inc. | Expandable catheter system for fluid injection into and deep to the wall of a blood vessel |
| US9526827B2 (en) | 2012-10-29 | 2016-12-27 | Ablative Solutions, Inc. | Peri-vascular tissue ablation catheter with support structures |
| US9301795B2 (en) | 2012-10-29 | 2016-04-05 | Ablative Solutions, Inc. | Transvascular catheter for extravascular delivery |
| US10226278B2 (en) | 2012-10-29 | 2019-03-12 | Ablative Solutions, Inc. | Method for painless renal denervation using a peri-vascular tissue ablation catheter with support structures |
| US10736656B2 (en) | 2012-10-29 | 2020-08-11 | Ablative Solutions | Method for painless renal denervation using a peri-vascular tissue ablation catheter with support structures |
| US10881458B2 (en) | 2012-10-29 | 2021-01-05 | Ablative Solutions, Inc. | Peri-vascular tissue ablation catheters |
| US10945787B2 (en) | 2012-10-29 | 2021-03-16 | Ablative Solutions, Inc. | Peri-vascular tissue ablation catheters |
| CN105101979B (zh) | 2012-12-21 | 2021-10-08 | 安斯泰来再生医药协会 | 由多能干细胞制备血小板的方法及其组合物 |
| US9949652B2 (en) | 2013-10-25 | 2018-04-24 | Ablative Solutions, Inc. | Apparatus for effective ablation and nerve sensing associated with denervation |
| US9931046B2 (en) | 2013-10-25 | 2018-04-03 | Ablative Solutions, Inc. | Intravascular catheter with peri-vascular nerve activity sensors |
| US10517666B2 (en) | 2013-10-25 | 2019-12-31 | Ablative Solutions, Inc. | Apparatus for effective ablation and nerve sensing associated with denervation |
| US10286190B2 (en) | 2013-12-11 | 2019-05-14 | Cook Medical Technologies Llc | Balloon catheter with dynamic vessel engaging member |
| EP3288626B8 (en) | 2015-04-27 | 2025-12-10 | Tulavi Therapeutics, Inc. | Substances and compositions for use in blocking nerve regeneration |
| US10675085B2 (en) | 2015-11-23 | 2020-06-09 | Boston Scientific Scimed, Inc. | Devices and methods for enhanced denervation procedures |
| US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
| US10849685B2 (en) | 2018-07-18 | 2020-12-01 | Ablative Solutions, Inc. | Peri-vascular tissue access catheter with locking handle |
| US20200069366A1 (en) * | 2018-08-29 | 2020-03-05 | Boston Scientific Scimed, Inc. | Combination denervation therapy for glucose control in metabolic disorders |
| US12114919B2 (en) | 2018-10-24 | 2024-10-15 | Boston Scientific Scimed, Inc. | Movable electrodes for controlled irreversible electroporation ablative volumes |
| CN112085991A (zh) * | 2020-10-15 | 2020-12-15 | 福建中医药大学附属人民医院（福建省人民医院） | 一种疼痛医疗临床实训用神经节阻滞治疗训练模型 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344957A1 (de) * | 1993-12-30 | 1995-07-06 | Hoechst Ag | Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen |
| US6735471B2 (en) * | 1996-04-30 | 2004-05-11 | Medtronic, Inc. | Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure |
| NL1014380C2 (nl) * | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
| US20060167498A1 (en) * | 2001-07-23 | 2006-07-27 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease |
| US6978174B2 (en) * | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| CA2575458C (en) * | 2004-07-28 | 2015-06-02 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| CN105056408B (zh) * | 2006-06-28 | 2018-09-25 | 美敦力Af卢森堡公司 | 用于热诱导的肾神经调制的系统 |
| KR20090103903A (ko) * | 2006-12-27 | 2009-10-01 | 사노피-아벤티스 | 사이클로알킬아민 치환된 이소퀴놀론 및 이소퀴놀리논 유도체 |
| NZ710157A (en) * | 2009-04-22 | 2016-08-26 | Mercator Medsystems Inc | Use of guanethidine for treating hypertension by local vascular delivery |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| US8975233B2 (en) | 2010-01-26 | 2015-03-10 | Northwind Medical, Inc. | Methods for renal denervation |
-
2012
- 2012-10-25 JP JP2014539025A patent/JP2014532654A/ja active Pending
- 2012-10-25 EP EP12844191.2A patent/EP2770992A4/en not_active Withdrawn
- 2012-10-25 CN CN201610042158.4A patent/CN105688214A/zh active Pending
- 2012-10-25 CN CN201280064573.XA patent/CN104203233A/zh active Pending
- 2012-10-25 US US14/395,485 patent/US20150202220A1/en not_active Abandoned
- 2012-10-25 CA CA2853466A patent/CA2853466A1/en not_active Abandoned
- 2012-10-25 WO PCT/US2012/062006 patent/WO2013063331A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532654A5 (enExample) | ||
| Burghardt et al. | Chronic antidepressant treatment impairs the acquisition of fear extinction | |
| Zhang et al. | Endoplasmic reticulum stress is involved in restraint stress-induced hippocampal apoptosis and cognitive impairments in rats | |
| Graeff | The antiaversive action of drugs | |
| BRPI0818623A2 (pt) | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal | |
| JP2010523714A5 (enExample) | ||
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| WO2008103993A3 (en) | Compositions and methods for treating glycogen storage diseases | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| JP2014528474A5 (enExample) | ||
| JP2010222367A5 (enExample) | ||
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2014002460A (es) | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso. | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX358492B (es) | Suministro intraventricular lento. | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| Santisteban et al. | Dysfunctional brain-bone marrow communication: a paradigm shift in the pathophysiology of hypertension | |
| MY157513A (en) | A water-in-oil type emulsion for treating a disease of the eye | |
| JP2016535780A5 (enExample) | ||
| AR072954A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase | |
| WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
| JP2011518165A (ja) | 疼痛、炎症、ニューロンもしくは血管損傷に対する生物学的マーカーおよび治療への応答、ならびにその使用方法 | |
| Talman et al. | Sudden death following selective neuronal lesions in the rat nucleus tractus solitarii | |
| Hoy Jr et al. | Acute theophylline exposure modulates breathing activity through a cervical contusion |